Description

Administering Practitioner Daniela Jennifer Wyatt continues the process of fulfilling Dr. Ramon Michael Bradshaw's vaccine order for Alexandria Montoya (DOB: 03/27/2012).

Daniela Jennifer Wyatt recalls there was only one potent (i.e., not expired) GARDASIL 9 - HPV9 product in the vaccine storage unit (Lot Number IIPVAXN08).

Daniela Jennifer Wyatt notes that lot number IIPVAXN08 for GARDASIL 9 - HPV9 was paid for using Private funds which conflicts with the vaccine program eligibility for Alexandria Montoya (DOB: 03/27/2012), VFC eligible - Medicaid/Medicaid Managed Care

After determining infrequent replenishment is allowed by the State VFC Program and to ensure the patient begins the HPV9 series, Daniela Jennifer Wyatt decides to use lot number IIPVAXN08 for today's visit and replace the privately funded vaccine after the next VFC vaccine order is received.

Pre-condition

(1) The patient, Alexandria Jacqueline Montoya (DOB 03/27/2012), is registered in the SUT.

(2) Two vaccine items are stored in the clinic's vaccine storage unit, both for GARDASIL 9 (HPV 9), one is publicly funded and expired (Lot Number IIPVAXN09) and the other (Lot Number IIPVAXN08) is privately funded and unexpired (i.e., still potent).

(3) Dr. Bradshaw has ordered an HPV9 vaccine for Alexandria Jacqueline Montoya (DOB 03/27/2012). in step 3.10.2

(4) Daniela Jennifer Wyatt, the administering practitioner, has opened the SUT's records for Alexandria Jacqueline Montoya (DOB 03/27/2012).

(5) Infrequent replenishment is allowed by the State VFC Program.

Post-Condition

The SUT makes the mismatch of the vaccine product's funding source and the patient's vaccine program eligibility visually apparent to the administering practitioner or does not permit the administering practitioner from selecting the mismatched vaccine.

Alexandria Jacqueline Montoya (DOB 03/27/2012) is vaccinated with GARDASIL 9 - HPV9 lot number IIPVAXN08, and this information is incorporated into the SUT.

Go to step 5.7.1 to transmit this vaccine administration.

Test Objectives

To test the capability that the SUT allows the administering practitioner be aware of a mismatch of the vaccine product's funding source and the patient's vaccine program eligibility.

Evaluation Criteria

The SUT distinguishes the publicly funded vaccine dose from the privately funded doses and is visually apparent to the administering practitioner. Alternatively, the SUT may prevent publicly funded vaccine doses from being visible or selected by users.

The selection workflow includes clear evidence of a vaccine funding source in at least one of the following ways

(only 1 method is required):

- Passive: The vaccine product that is privately funded is not displayed by the SUT (i.e., cannot be chosen)
- Passive: The display of selectable vaccine products which includes the funding source are displayed with some indication that choosing the wrong funding sourced product is discouraged (e.g., hover over tooltip, color, bolding, graying out, or other UI indication used by the SUT for similar issues)
- Active: Selection of a specific privately funded vaccine product to administer generates informative messages in a method consistent with the SUT for similar issues) - Active informing

The SUT makes the mismatch of the vaccine product's funding source and the patient's vaccine program eligibility visually apparent to the administering practitioner or does not permit the administering practitioner from selecting the mismatched vaccine.

Vaccine Funding Source	Private funds
Patient Dose-level Eligibility for Vaccines for Children	VFC eligible - Medicaid/Medicaid Managed Care

The SUT may meet the requirement by prohibiting the selection of mismatch. However, careful consideration should be made when implementing such a strategy. This may result in patients not being immunized in a timely manner.

The following information is a not evaluated portion of this test step but supports subsequent test steps and should be performed by the SUT user:

Alexandria Jacqueline Montoya (DOB 03/27/2012) is administered vaccines by Nurse Daniela Jennifer Wyatt who enters the following information into the SUT:

Product Name (This may vary with each implementation)	GARDASIL 9 00006-4121-01
Date Administered	Today's Date
Unit-of-Use (Syringe or Vial) NDC	00006-4121-01
Manufacturer	Merck and Co., Inc.
Lot Number	IIPVAXN08
Expiration Date	09/27/2029
Unit-of-Use (Vial/Syringe) Image that may be scanned.	
GTIN 00300064121018	
Patient Dose-level Eligibility for Vaccines for Children	VFC eligible - Medicaid/Medicaid Managed Care
Vaccine Funding Source	Private funds
Route	INTRAMUSCULAR
Site	Left Deltoid
VIS Given	HPV (Human Papillomavirus) Vaccine VIS - 08/06/2021
CVX	165
MVX	MSD
Funding Source Code	PHC70
Packaging	10 pack – 1 dose syringe
Trade Name	GARDASIL 9
Generic Name (CVX 165)	HPV9

Notes

The VIS encoded value that is associated with the most current VIS for the vaccines and evaluated in the transmit message, can be found in the CDC VIS Lookup Table located here:
https://www.cdc.gov/vaccines/programs/iis/code-sets/vis-barcode-lookup-table.html